
Novo’s Experimental Weight-Loss Drug Delivers 25% Average Loss in Women
Novo Nordisk’s experimental CagriSema has produced a reported 25 per cent average weight reduction in women in a later analysis of the REDEFINE 1 clinical trial. This episode explains the finding, the results across menopause stages and the questions that remain.
Understand how the injection combines semaglutide with cagrilintide, why the original study produced different overall weight-loss estimates, and what researchers mean by a post hoc analysis. We also examine the broader trial’s gastrointestinal side effects and why reproductive-stage comparisons cannot establish that menopause itself…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.